Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan Othus

Showing results (191-200 of 232) with videos related to

Pageof 24
Sort By:
NPJ Precision Oncology|January 24, 2025
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinomaSandip P Patel, Eleanor Cano-Linson, Young Kwang Chae, et al.
Cancer Communications (London, England)|May 22, 2025
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohortYoung Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
Leukemia|May 4, 2018
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasmsAnna B Halpern, Megan Othus, Emily M Huebner, et al.
American Journal of Hematology|November 23, 2017
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemiaRoland B Walter, Laura C Michaelis, Megan Othus, et al.
JCO Oncology Practice|June 23, 2026
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 TherapyMegan Othus, Thach-Giao Truong, Elad Sharon, et al.
Biopreservation and Biobanking|November 28, 2017
Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG ReportEra L Pogosova-Agadjanyan, Anna Moseley, Megan Othus, et al.
Journal of Gynecologic Oncology|April 17, 2026
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort resultsYoung Kwang Chae, Josie Czeskleba, Sandip Pravin Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2015
Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council reportFabiana Ostronoff, Megan Othus, Michelle Lazenby, et al.
Transplantation and Cellular Therapy|May 6, 2024
Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid NeoplasmsNoam E Kopmar, Megan Othus, Kim Quach, et al.
Blood Advances|October 20, 2017
US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALLFarhad Ravandi, Megan Othus, Susan M O'Brien, et al.
Pageof 24

Showing results (191-200 of 232) with videos related to

Sort By:
Pageof 24
NPJ Precision Oncology|January 24, 2025
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinomaSandip P Patel, Eleanor Cano-Linson, Young Kwang Chae, et al.
Cancer Communications (London, England)|May 22, 2025
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohortYoung Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
Leukemia|May 4, 2018
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasmsAnna B Halpern, Megan Othus, Emily M Huebner, et al.
American Journal of Hematology|November 23, 2017
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemiaRoland B Walter, Laura C Michaelis, Megan Othus, et al.
JCO Oncology Practice|June 23, 2026
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 TherapyMegan Othus, Thach-Giao Truong, Elad Sharon, et al.
Biopreservation and Biobanking|November 28, 2017
Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG ReportEra L Pogosova-Agadjanyan, Anna Moseley, Megan Othus, et al.
Journal of Gynecologic Oncology|April 17, 2026
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort resultsYoung Kwang Chae, Josie Czeskleba, Sandip Pravin Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2015
Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council reportFabiana Ostronoff, Megan Othus, Michelle Lazenby, et al.
Transplantation and Cellular Therapy|May 6, 2024
Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid NeoplasmsNoam E Kopmar, Megan Othus, Kim Quach, et al.
Blood Advances|October 20, 2017
US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALLFarhad Ravandi, Megan Othus, Susan M O'Brien, et al.
Pageof 24